Tredje AP fonden Cuts Position in Bristol-Myers Squibb Co (BMY)
Tredje AP fonden cut its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 4.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 294,629 shares of the biopharmaceutical company’s stock after selling 13,233 shares during the period. Bristol-Myers Squibb accounts for approximately 0.6% of Tredje AP fonden’s portfolio, making the stock its 28th largest position. Tredje AP fonden’s holdings in Bristol-Myers Squibb were worth $16,022,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. American National Bank increased its position in shares of Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 508 shares in the last quarter. Welch Investments LLC increased its position in shares of Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares in the last quarter. Crestwood Advisors Group LLC acquired a new position in shares of Bristol-Myers Squibb during the first quarter worth approximately $116,000. Blue Chip Partners Inc. increased its position in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of Bristol-Myers Squibb by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 60 shares in the last quarter. 69.79% of the stock is currently owned by institutional investors and hedge funds.
Bristol-Myers Squibb Co (NYSE:BMY) opened at 56.30 on Tuesday. Bristol-Myers Squibb Co has a one year low of $46.01 and a one year high of $64.77. The firm’s 50-day moving average is $55.55 and its 200 day moving average is $54.50. The firm has a market capitalization of $92.33 billion, a price-to-earnings ratio of 20.56 and a beta of 1.17.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 17.92% and a return on equity of 25.24%. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.69 EPS. Analysts forecast that Bristol-Myers Squibb Co will post $2.97 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 2.77%. The ex-dividend date of this dividend was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.
COPYRIGHT VIOLATION WARNING: “Tredje AP fonden Cuts Position in Bristol-Myers Squibb Co (BMY)” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/08/tredje-ap-fonden-cuts-position-in-bristol-myers-squibb-co-bmy.html.
BMY has been the topic of a number of research reports. Jefferies Group LLC reissued a “buy” rating and issued a $64.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, June 5th. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $59.88 target price on the stock. in a research note on Monday, April 24th. BidaskClub raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Cowen and Company set a $65.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, July 10th. Finally, Deutsche Bank AG set a $55.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, July 17th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $63.33.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter.